Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study.

Sudha VisvanathanStefan DanilukRafał PtaszyńskiUlf Müller-LadnerMeera RamanujamBernd RosenstockAnastasia G EleftherakiRichard ViniskoAlena PetříkováHerbert KellnerEva DokoupilovaBrygida KwiatkowskaRieke AltenChristian SchwabePatrick BaumDavid JosephJay S FineSteven J PadulaJürgen Steffgen

Published in: Annals of the rheumatic diseases (2019)

NCT01751776.

Keyphrases

placebo controlled
double blind
rheumatoid arthritis
clinical trial
study protocol
phase iii
phase ii
phase ii study
open label
disease activity
radiation therapy
squamous cell carcinoma
ankylosing spondylitis
rectal cancer
systemic lupus erythematosus